Cargando…
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
BACKGROUND: Gemcitabine and docetaxel have been shown to be active in pre-treated relapsed leiomyosarcoma. This study investigated the combination as first line treatment in patients with unresectable locally advanced/metastatic leiomyosarcoma. METHODS: Patients received gemcitabine 900 mg/m(2) days...
Autores principales: | Seddon, Beatrice, Scurr, Michelle, Jones, Robin L, Wood, Zoe, Propert-Lewis, Cerys, Fisher, Cyril, Flanagan, Adrienne, Sunkersing, Jonanthan, A’Hern, Roger, Whelan, Jeremy, Judson, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434867/ https://www.ncbi.nlm.nih.gov/pubmed/25987978 http://dx.doi.org/10.1186/s13569-015-0029-8 |
Ejemplares similares
-
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
por: Seddon, Beatrice, et al.
Publicado: (2017) -
Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines
por: Lopez-Acevedo, Micael, et al.
Publicado: (2014) -
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016) -
Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus
por: Wang, Connor, et al.
Publicado: (2020) -
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)